Chardan Capital Keeps Their Buy Rating on Metagenomi, Inc. (MGX)

Tip Ranks
2025.11.12 22:35
portai
I'm PortAI, I can summarize articles.

Chardan Capital analyst Geulah Livshits has maintained a Buy rating on Metagenomi, Inc. (MGX) with a price target of $7.00. Livshits, who focuses on the Healthcare sector, has an average return of 22.2% and a 41.55% success rate on recommended stocks. Additionally, TD Cowen's Joseph Thome also issued a Buy rating for Metagenomi, while TR | OpenAI reiterated a Hold rating on November 8.

Chardan Capital analyst Geulah Livshits maintained a Buy rating on Metagenomi, Inc. today and set a price target of $7.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Lexeo Therapeutics, Inc., and Intellia Therapeutics. According to TipRanks, Livshits has an average return of 22.2% and a 41.55% success rate on recommended stocks.

In addition to Chardan Capital, Metagenomi, Inc. also received a Buy from TD Cowen’s Joseph Thome in a report issued yesterday. However, on November 8, TR | OpenAI – 4o reiterated a Hold rating on Metagenomi, Inc. (NASDAQ: MGX).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.